About concomitant KRAS and other molecular alterations in non–small cell lung cancers

In this letter, we aim to report the frequency of double mutants (ie, KRAS and another oncogenic alteration) in a case series of patients with advanced NSCLC tested for EGFR, ALK, ROS1, BRAF and KRAS alterations for therapeutic purposes. [...]beyond the classical mutual exclusivity of driver molecular alterations in NSCLC, some samples can nevertheless contain double mutations. The necessity of diagnosing double mutations emphasizes the need to analyze concurrently the panel of EGFR, BRAF, ALK, ROS1 and KRAS genes [5].Acknowledgements The authors would like to acknowledge the technical staff of the Department of Pathology (CHRU Brest) for their contributions in molecular analyses as well as the thoracic oncologists and molecular geneticists of the Brest University Hospital for their daily collaboration.